Rhythm Pharmaceuticals director proposes $1.07M sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rhythm Pharmaceuticals, Inc. (RYTM) director Christophe Jean reported a proposed sale of 10,000 common shares, with an aggregate market value of $1,074,800 and an approximate sale date of November 17, 2026. The shares were acquired from the issuer through exercise of stock options on November 17, 2026, with cash payment. Morgan Stanley Smith Barney LLC is listed as broker.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.